Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation--a prospective, randomized, double-blind study
| Autor: | Monica A. Slavin, Roger Adams, A R Feldman, H G Schoch, Barbara A. Osborne, M J Levenstein, Raleigh A. Bowden, Joel D. Meyers |
|---|---|
| Rok vydání: | 1995 |
| Předmět: |
Adult
Male medicine.medical_specialty Adolescent medicine.medical_treatment Drug resistance Opportunistic Infections Placebo Gastroenterology Double-Blind Method Internal medicine Amphotericin B medicine Immunology and Allergy Humans Prospective Studies Candida albicans Fluconazole Mycosis Bone Marrow Transplantation Candida Chemotherapy biology business.industry Candidiasis Drug Resistance Microbial Middle Aged medicine.disease biology.organism_classification Survival Analysis Surgery Transplantation Infectious Diseases Patient Compliance Female business medicine.drug |
| Zdroj: | The Journal of infectious diseases. 171(6) |
| ISSN: | 0022-1899 |
| Popis: | A randomized, double-blind, placebo-controlled trial assessed the efficacy and toxicity of 400 mg/day fluconazole in preventing fungal infections during the first 75 days after marrow transplantation. During prophylaxis, systemic fungal infections occurred in 10 (7%) of 152 fluconazole-treated patients compared with 26 (18%) of 148 placebo-treated patients (P = .004). There were no Candida albicans infections in fluconazole recipients compared with 18 in placebo recipients (P < .001) and no significant increase in Candida infections other than C. albicans. Fluconazole also significantly reduced the incidence of superficial fungal infections (P < .001), fungal colonization (P = .037), and empiric amphotericin B use (P = .005). The probability of survival was improved in fluconazole recipients, in whom 31 deaths occurred up to day 110 after transplantation compared with 52 deaths in placebo recipients (P = .004). No clinically significant toxicity was detected with fluconazole use. Prophylactic fluconazole was safe and significantly reduced systemic fungal infections with other benefits, including improved survival at day 110 after marrow transplantation. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|